Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.61 |
| ▸ | NOS2 | P35228 | 4/20 | 0.61 |
| ▸ | NOS1 | P29475 | 3/20 | 0.61 |
| ▸ | GABRP | O00591 | 2/20 | 0.53 |
| ▸ | GABRD | O14764 | 2/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.53 |
| ▸ | GABRE | P78334 | 2/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29481452 | 0.98 | NOS3 (0.59) | NOS3NOS2NOS1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL6953232 | 0.98 | NOS3 (0.59) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL339608 | 0.82 | — | — | |
| SCHEMBL29481458 | 0.82 | — | — | |
| SCHEMBL318127 | 0.81 | NOS3 (0.59) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL105611 | 0.81 | NOS2 (0.70) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL318128 | 0.81 | NOS3 (0.59) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL18476749 | 0.81 | NOS3 (0.59) | NOS3NOS2NOS1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL23064166 | 0.80 | NOS3 (0.63) | NOS3NOS2NOS1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL14630870 | 0.79 | NOS2 (0.68) | NOS3NOS2NOS1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5399294-A | Dispersing agents, their use and solids coated therewith | EFKA-CHEMICALS B.V. (NL) | 1995-03-21 | — | — | US | claimed |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113795249-A | Pharmaceutical compounds for the treatment of complement-mediated disorders | 艾其林医药公司 | 2021-12-14 | — | — | CN | disclosed |
| WO-2020198062-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| EP-1948717-B1 | USE OF A DRY POWDER OF A POLYMERIC ADDITIVE | BASF SE (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-20090156739-A1 | Process for the Preparation of a Dry Powder of a Polymeric Additive | CIBA CORP. | 2009-06-18 | — | — | US | disclosed |
| EP-1948717-A1 | PROCESS FOR THE PREPARATION OF A DRY POWDER OF A POLYMERIC ADDITIVE | Ciba Specialty Chemicals Holding Inc. (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007057326-A1 | PROCESS FOR THE PREPARATION OF A DRY POWDER OF A POLYMERIC ADDITIVE | CIBA HOLDING INC. (CH) | 2007-05-24 | — | — | WO | disclosed |
| EP-0674623-B1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6403578-B1 | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| CN-1215054-A | Bychclic fibrinogen antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-04-28 | — | — | CN | disclosed |
| CN-1209060-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-02-24 | — | — | CN | disclosed |
| CN-1041921-C | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | disclosed |
| US-5852045-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0674623-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014776-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | NOS3 4386/4885NOS2 4540/4885NOS1 4498/4885 |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, CFH, C1QBP | NOS3 4386/4885NOS2 4540/4885NOS1 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.